243 related articles for article (PubMed ID: 26210594)
1. Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?
Zeman M; Vecka M; Perlík F; Hromádka R; Staňková B; Tvrzická E; Žák A
Med Sci Monit; 2015 Jul; 21():2156-62. PubMed ID: 26210594
[TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic role of niacin in dyslipidemia management.
Boden WE; Sidhu MS; Toth PP
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
[TBL] [Abstract][Full Text] [Related]
4. Pleiotropic effects of niacin: Current possibilities for its clinical use.
Zeman M; Vecka M; Perlík F; Staňková B; Hromádka R; Tvrzická E; Širc J; Hrib J; Žák A
Acta Pharm; 2016 Dec; 66(4):449-469. PubMed ID: 27749252
[TBL] [Abstract][Full Text] [Related]
5. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
6. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
7. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
8. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
Yim BT; Chong PH
Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
[TBL] [Abstract][Full Text] [Related]
9. Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
Haynes R; Valdes-Marquez E; Hopewell JC; Chen F; Li J; Parish S; Landray MJ; Armitage J; ; ;
Clin Ther; 2019 Sep; 41(9):1767-1777. PubMed ID: 31447131
[TBL] [Abstract][Full Text] [Related]
10. Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.
Kent S; Haynes R; Hopewell JC; Parish S; Gray A; Landray MJ; Collins R; Armitage J; Mihaylova B;
Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):348-54. PubMed ID: 27407053
[TBL] [Abstract][Full Text] [Related]
11. Niacin, an old drug with a new twist.
Song WL; FitzGerald GA
J Lipid Res; 2013 Oct; 54(10):2586-94. PubMed ID: 23948546
[TBL] [Abstract][Full Text] [Related]
12. Clinical update on the use of niacin for the treatment of dyslipidemia.
Berra K
J Am Acad Nurse Pract; 2004 Dec; 16(12):526-34. PubMed ID: 15645997
[TBL] [Abstract][Full Text] [Related]
13. Nicotinic acid as a lipid-modifying drug--a review.
Julius U; Fischer S
Atheroscler Suppl; 2013 Jan; 14(1):7-13. PubMed ID: 23357134
[TBL] [Abstract][Full Text] [Related]
14. Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol.
Wright RS
Curr Opin Cardiol; 2013 Jul; 28(4):389-98. PubMed ID: 23736814
[TBL] [Abstract][Full Text] [Related]
15. A case for immediate-release niacin.
Bassan M
Heart Lung; 2012; 41(1):95-8. PubMed ID: 21414665
[TBL] [Abstract][Full Text] [Related]
16. [Niacin--an additive therapeutic approach for optimizing lipid profile].
Wieneke H; Schmermund A; Erbel R
Med Klin (Munich); 2005 Apr; 100(4):186-92. PubMed ID: 15834527
[TBL] [Abstract][Full Text] [Related]
17. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.
Toth PP; Zarotsky V; Sullivan JM; Laitinen D
Curr Med Res Opin; 2009 Jun; 25(6):1355-63. PubMed ID: 19425901
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
McKenney JM
Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
[TBL] [Abstract][Full Text] [Related]
19. Niacin for dyslipidemia: considerations in product selection.
McKenney J
Am J Health Syst Pharm; 2003 May; 60(10):995-1005. PubMed ID: 12789870
[TBL] [Abstract][Full Text] [Related]
20. Niacin: chemical forms, bioavailability, and health effects.
MacKay D; Hathcock J; Guarneri E
Nutr Rev; 2012 Jun; 70(6):357-66. PubMed ID: 22646128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
